Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Ventures Raises $230M for First Fund

NEW YORK (GenomeWeb) – Illumina Ventures has raised $230 million for its first fund, which focuses on supporting firms involved in genomics and precision medicine.

Illumina launched the independent, early-stage venture capital firm in 2016 with an investment of $100 million. Since launching, it has raised an additional $130 million from a mix of corporate, institutional, sovereign, and individual investors.

The investment will "allow us to expand our team and support a greater number of entrepreneurs," Nicholas Naclerio, founding partner of Illumina Ventures, said in a statement.

Thus far, the firm has invested in seven companies: Biota Technology, DNA Script, Encoded Genomics, Genome Medical, Kallyope, SerImmune, and Twist Bioscience.

"The rapid advances in genomics are creating tremendous entrepreneurial opportunities across industries from novel therapeutics, diagnostics, and research tools to food security and synthetic biology," Francis deSouza, president and CEO of Illumina, said in a statement.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.